Hybrid Fractional Laser for Treatment of Off Face Body Skin Quality
Non-Randomized, Open-label, Blinded Evaluator Study Characterizing Effectiveness of Hybrid Fractional Laser for the Treatment of Off Face Body Skin Quality
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Montclair, New Jersey, United States, 07042
- New Jersey Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male/female subjects between 40 to 65 years of age inclusive
- Fitzpatrick skin type I-III
- Non-smokers or have not smoked (including vaping) within the past 14 days from the screening visit
- Has poor skin texture
- Has mild thin skin
- Has some level of dyschromia on the treatment area as assessed by the Investigator
- Can read, understand and sign informed consent form (English only)
- Has indicated willingness to participate in the study by signing an informed consent form
- Agrees to adhere to the treatment and follow-up schedule and post treatment care instructions
Exclusion Criteria:
- Fitzpatrick skin type IV-VI
- Has tanned within the past 30 days or is unable or unlikely to refrain from tanning, including the use of tanning booths, tanning spray or cream
- Has tattoos, dysplastic nevi on the treatment area
- Is pregnant and/or lactating
- History or current photosensitivity
- History or current use of medication with photosensitizing properties within past 6 months
- History or current of chronic reoccurring skin disease or disorder affecting treatment area
- History or current cancer of any type
- Has signs of actinic bronzing
- Has open lacerations, and abrasions on the treatment area
- History of keloid formation, or hypertrophic scar formation, or poor wound healing
- History of bleeding disorder, or is currently taking anticoagulation medications
- Has significant concurrent illnesses (controlled or uncontrolled), such as diabetes, lupus, epilepsy, or cardiac disorders, which might be aggravated as a result of treatment
- Has participated in any clinical trial involving an investigational drug, device or cosmetic product or procedure within the past 30 days
- The investigator feels that for any reason the subject is not eligible to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hybrid Fractional Laser
Hybrid Fractional Laser Treatment
|
Hybrid Fractional Laser Device
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Photography
Time Frame: 3 months
|
Evaluate improvement in photography using Physicians Global Assessment Scale (0-4) where 0 is no change and 4 is very significant improvement.
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HALOCIP002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.